The 2023-2028 Outlook for Chest Freezers in India

This study covers the latent demand outlook for chest freezers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cherry-Flavored Bottled Waters in India

This study covers the latent demand outlook for cherry-flavored bottled waters across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in quest...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Chemotherapy-Induced Serotonin Receptor Antagonists for Nausea and Vomiting Drugs in India

This study covers the latent demand outlook for chemotherapy-induced serotonin receptor antagonists for nausea and vomiting drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Chemotherapy-Induced Nausea and Vomiting Drugs in India

This study covers the latent demand outlook for chemotherapy-induced nausea and vomiting drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For ea...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Chemotherapy for Endometrial Cancers in India

This study covers the latent demand outlook for chemotherapy for endometrial cancers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Chemotherapy and Other Multiple Myeloma Therapeutics in India

This study covers the latent demand outlook for chemotherapy and other multiple myeloma therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Chemotherapy and Antibody Combination Antibody Therapies in India

This study covers the latent demand outlook for chemotherapy and antibody combination antibody therapies across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in Ind...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Chemicals in India

This study covers the latent demand outlook for chemicals across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent shar...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cheese Snack Crackers in India

This study covers the latent demand outlook for cheese snack crackers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Cheese Powders in India

This study covers the latent demand outlook for cheese powders across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent...

9/14/2022 | India Outlook 2023

This study covers the latent demand outlook for chest freezers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chest freezers. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chest freezers as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AB Electrolux, Beverage-Air, Brandt France, BSH Household Appliances Manufacturing Pvt, DAIHAN Scientific Company, Haier Group, Hengel Industrie, Hitachi, LG Electronics, Liebherr Group, Panasonic Corporation, Thermo Fisher Scientific, and Whirlpool Corporation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cherry-flavored bottled waters across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cherry-flavored bottled waters. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cherry-flavored bottled waters as including all commonly understood products falling within this broad category, such as varieties of packaged water, such as artisan, drinking, mineral, purified, sparkling, and spring waters, which have been enhanced with natural or artificial cherry flavoring, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Groupe Danone, Nestlé Waters, PepsiCo, and The Coca-Cola Company. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for chemotherapy-induced serotonin receptor antagonists for nausea and vomiting drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chemotherapy-induced serotonin receptor antagonists for nausea and vomiting drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chemotherapy-induced serotonin receptor antagonists for nausea and vomiting drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acacia Pharma Group, Aphios, Baxter International, Dr. Reddy's Laboratories, Eisai Company, Especificos Stendhal, F. Hoffmann-La Roche, GlaxoSmithKline, Helsinn Healthcare, Heron Therapeutics, Kyowa Hakko Kirin Company, Lee's Pharmaceutical Holdings, Merck & Company, Midatech Pharma, Mundipharma Pte, Mylan NV, Ono Pharmaceutical Company, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical Company, Purdue Pharma, Sandoz International, SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma, Specialised Therapeutics Asia Pte, Sun Pharmaceutical Industries, TAIHO Pharmaceutical Company, Tesaro, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for chemotherapy-induced nausea and vomiting drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chemotherapy-induced nausea and vomiting drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chemotherapy-induced nausea and vomiting drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acacia Pharma Group, Aphios, Baxter International, Dr. Reddy's Laboratories, Eisai Company, Especificos Stendhal, F. Hoffmann-La Roche, GlaxoSmithKline, Helsinn Healthcare, Heron Therapeutics, Kyowa Hakko Kirin Company, Lee's Pharmaceutical Holdings, Merck & Company, Midatech Pharma, Mundipharma Pte, Mylan NV, Ono Pharmaceutical Company, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical Company, Purdue Pharma, Sandoz International, SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma, Specialised Therapeutics Asia Pte, Sun Pharmaceutical Industries, TAIHO Pharmaceutical Company, Tesaro, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for chemotherapy for endometrial cancers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chemotherapy for endometrial cancers. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chemotherapy for endometrial cancers as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, ARIAD Pharmaceuticals, Becton, Dickinson and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Company, Novartis, Sanofi, and Siemens Healthineers. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for chemotherapy and other multiple myeloma therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chemotherapy and other multiple myeloma therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chemotherapy and other multiple myeloma therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen Biotech, Juno Therapeutics, Kesios Therapeutics, Novartis International, and Sanofi Genzyme. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for chemotherapy and antibody combination antibody therapies across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chemotherapy and antibody combination antibody therapies. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chemotherapy and antibody combination antibody therapies as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Amgen, Biogen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche, Genmab, Novartis, Sanofi, and Seattle Genetics. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for chemicals across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for chemicals. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chemicals as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aarti Industries, Aditya Birla Ch, BASF, Bayer, DuPont de Nemours, ExxonMobil Chemical, Guj Alkali, Huntsman International, India Glycols, IOL Chemicals, Phillips Carbon, Pidilite Industries, Tata Chemicals, The DOW Chemical Company, and UPL. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cheese snack crackers across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cheese snack crackers. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cheese snack crackers as including all commonly understood products and/or services falling within this broad category, such as wafers and biscuits made from unsweetened dough that have been enhanced with natural and artificial cheese flavors, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Pepperidge Farm and Sunshine. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for cheese powders across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for cheese powders. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of cheese powders as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aarkay Food Products, ADM WILD Europe Gmbh & CompanyKg, All American Foods, Archer Daniels Midland, Arla Foods, Bluegrass Dairy & Food, Cargill, Commercial Creamery Company, Dairiconcepts, Di Bruno Bros., DSM Nutritional Products, E. I. Du Pont De Nemours and Company, Frontier Co-op, Kanegrade, Kerry Group, Kraft Foods, L.P, Lactosan, Land O’Lakes, The Kraft Heinz Company, and Vita Organic. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT